Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Pharmaceutical companies

Pfizer loses appeal in patent case concerning Lyrica use in pain relief

The Court of Appeal in London ruled on 13 October 2016 that it has upheld last year’s High Court decision that the patent covering Lyrica for pain relief has not been infringed by generic drug manufacturers Actavis and Mylan. 

The drug’s manufacturer, Pfizer, says that it will seek a further appeal on the ruling.

Pfizer developed Lyrica (pregabalin) for the treatment of generalised anxiety disorder (GAD) and epilepsy, but the patent for this indication expired in 2013. When Pfizer discovered that pregabalin could also relieve pain, it took out a second medical use patent for Lyrica to cover this use, which expires in July 2017. 

Meanwhile Actavis (now renamed Allergan) and Mylan launched their own generic versions of the drug to treat GAD and epilepsy.

Pfizer then claimed in December 2014 that Lyrica’s second medical use patent was being breached and took Actavis and Mylan to the High Court over patent infringement. Pfizer argued that it was inevitable that the generic version would be used for other conditions, but lost the case in September 2015.

A statement from Pfizer, published on 13 October 2016, says that it “maintains its strong belief in the validity and importance of the second medical use patent for the use of Lyrica in pain and intends to seek permission to appeal the decision to the Supreme Court”.

“Pfizer has always made clear that it has not sought to prevent the use of generic pregabalin to treat generalised anxiety disorder or epilepsy. Following the Court of Appeal’s judgement, and pending the outcome of its appeal to the Supreme Court, Pfizer will now seek to have the NHS England Pregabalin Guidance on prescribing and dispensing by brand name, Lyrica, limited to prescribing and dispensing for the types of pain in those patent claims upheld as valid by the Court of Appeal,” the statement says.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201836

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Lyrica packet

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.